Pharmacy Law

/Pharmacy Law

RXinsider Thought Leader Videos – What are Best Practices When Dealing with Marketers?

As part of a Thought Leader Video Series, Anthony Calamunci and Brian Dickerson were interviewed by RXinsider on the status of the Pharmacy industry.  Each week FisherBroyles will provide access to the industry specific Q&A interview sessions hosted by RXinsider so you can learn what the newest legal and industry issues are and how to [...]

RXinsider Thought Leader Videos – What is the Importance of Seeking Legal Counsel when Dealing with Issues of Compliance?

As part of a Thought Leader Video Series, Anthony Calamunci and Brian Dickerson were interviewed by RXinsider on the status of the Pharmacy industry. Each week FisherBroyles will provide access to the industry specific Q&A interview sessions hosted by RXinsider so you can learn what the newest legal and industry issues are and how to [...]

Client Alert – CVS Pitches A New Plan to Combat High Drug Prices

CVS Health has introduced a white paper highlighting several new techniques it claims will reduce the cost of drugs (“Current and New Approaches to Making Drugs More Affordable”). CVS determines that these new techniques, together with several approaches already in use, will help patients afford the medications they need (thus ensuring that more people take [...]

RXinsider Thought Leader Videos – What to Expect Regarding the PBMs’ Ongoing War Against Independent Pharmacies?

As part of a Thought Leader Video Series, Anthony Calamunci and Brian Dickerson were interviewed by RXinsider on the status of the Pharmacy industry. Each week FisherBroyles will provide access to the industry specific Q&A interview sessions hosted by RXinsider so you can learn what the newest legal and industry issues are and how to [...]

Client Alert – OIG Issues Advisory Opinion on Provision of Cost-Free Telemedicine Hardware and Services

The Health and Human Services Office of Inspector General (OIG) recently issued Advisory Opinion No. 18-03 (the “Opinion”) on a question regarding the possible application of the Anti-Kickback Statute in a proposed arrangement between a federally qualified health center look-alike (the “Provider”) and a county clinic (the “Clinic”). In the arrangement, the Provider would give, [...]

RXinsider Thought Leader Videos – Implications of FWA and False Claims

As part of a Thought Leader Video Series, Anthony Calamunci and Brian Dickerson were interviewed by RXinsider on the status of the Pharmacy industry. Each week FisherBroyles will provide access to the industry specific Q&A interview sessions hosted by RXinsider so you can learn what the newest legal and industry issues are and how to [...]

RXinsider is Proud to Present FisherBroyles as a Thought Leader in Health and Pharmacy Law

In FisherBroyles' NEW Thought Leader Video Series, Brian E. Dickerson, JD, Partner, and Anthony J. Calamunci, JD, CFE, Partner, discuss health and pharmacy law and how they can assist in multifaceted and complex issues within the industry. Topics include: The importance of seeking legal counsel for compliance programs. Best practices for affiliating with outside entities [...]

Drug Diversion Scheme Earns Houston Man 15-Year Stint in Federal Prison

On July 17, 2018, the former president of Cumberland Distribution, Inc. (Cumberland) was sentenced to 15 years in prison and ordered to forfeit $1.4 million for his leading role in a drug diversion plot in which tainted pharmaceuticals were shipped to pharmacies nationwide from a Nashville warehouse. Jerrod Nichols Smith and his co-conspirators, Charles Jeffrey [...]

DOJ Announces Revised Opioid Anti-Diversion Policy

Last week, the Department of Justice (DOJ) announced that it had finalized new rules to prevent the diversion of prescription opioids in a move designed to curb the national opioid crisis.  The rules, initially proposed in April 2018, received over 1600 comments during a 30-day comment period. A DOJ summary of the new rules notes that the [...]

GAO Issues Report Critical of 340B Contract Pharmacy Oversight

Late last month the Government Accountability Office (GAO) released a report entitled, “Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement”. The 60-page Report details a number of weaknesses in the 340B Drug Pricing Program, particularly as it regards the oversight of contract pharmacies by the Department of Health and Human [...]